Work

A phase 3 trial of adagloxad simolenin/OBI-821 in patients with high-risk early-stage triple-negative breast cancer.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.2551

Authors: Hope S. Rugo, Bernardo Leon Rapoport, Javier Cortes, Carlos H. Barrios, Rita Nanda, Sung-Bae Kim, Binghe Xu, Chiun-Sheng Huang, Michelle E. Melisko, Daphne T. F. Tsoi, Claudio Lima Rocha, Zaida Morante, Keun Seok Lee, Maricela Garcia Garces, Dong Xu, Ingly Lee, Chu-Yun Chi, Chia Ling Chen

Institutions: City Of Hope National Medical Center, The Medical Oncology Centre of Rosebank, University of Pretoria, Latin American Cooperative Oncology Group (LACOG), University of Chicago, Asan Medical Center, University of Ulsan, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, National Taiwan University Hospital, University of California, San Francisco, St John of God Subiaco Hospital, Instituto Nacional de Enfermedades Neoplásicas, National Cancer Center, Instituto de Seguridad Social del Estado de México y Municipios

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162498182

Cites:

Cited by:

Related to: